Tucatinib Improves PFS, OS in HER2-Positive Metastatic Breast Cancer

Tucatinib showed improvements in survival in patients with HER2-positive breast cancer.

Source: CancerNetwork - October 24, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news